首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1452450

抗生素市場-依藥物類別（青黴素類、頭孢菌素類、大環內酯類、喹諾酮類、氨基糖苷類、四環素類）、類型、譜（寬、窄）、藥物來源、給藥途徑、應用、配銷通路、全球預測 2024-2032

Antibiotics Market - By Drug Class (Penicillins, Cephalosporins, Macrolides, Quinolones, Aminoglycosides, Tetracyclines), Type, Spectrum (Broad, Narrow), Drug Origin, Route of Administration, Application, Distribution Channel, Global Forecast 2024-2032

出版日期: 2024年02月01日 | 出版商:

Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球傳染病流行率不斷上升，預計 2024 年至 2032 年全球抗生素市場CAGR將達到 3.3%。

隨著人口成長和都市化進程加快，傳染病爆發的風險上升，對有效抗菌治療的需求增加。根據聯合國統計，2022年11月中旬全球人口達80億，未來30年將增加近20億。

此外，抗菌素抗藥性的持續挑戰凸顯了對創新抗生素的迫切需求。人們越來越關注醫療基礎設施的發展，尤其是在新興經濟體，加上全球醫療支出的不斷增加，擴大了對抗生素的需求，推動了市場向前發展。

抗生素市場根據藥物類別、類型、光譜、藥物來源、給藥途徑、應用、配銷通路和地區進行分類。

預計到 2032 年，青黴素領域的需求將錄得強勁，因為青黴素以其對抗從呼吸道感染到皮膚感染等多種細菌感染的功效而聞名。隨著醫療程序和手術的進步，術後感染的風險激增，需要使用青黴素等抗生素來預防和治療。新配方的不斷開發和聯合療法的引入增強了對該藥物類別的需求。

受成本效益、易於取得以及多種品牌抗生素專利到期等因素的推動，學名藥類型細分市場預計到 2032 年將產生巨額收入。學名藥為品牌抗生素提供了更實惠的替代品，這使得它們在已開發和發展中市場都特別有吸引力。此外，嚴格的法規核准和品質標準確保了學名藥抗生素的安全性和有效性，進一步推動了其在全球的採用。

受傳染病高發生率、完善的醫療基礎設施以及旨在對抗抗菌素抗藥性的強力的政府舉措等因素的推動，歐洲抗生素市場規模將在 2032 年大幅擴大。該地區各國優先考慮醫療保健，從而增加了對新型抗生素製劑和療法的研發活動的投資。此外，製藥公司和研究機構之間的策略合作有助於該地區在全球抗生素市場中佔據主導地位。

產業生態系統分析
產業影響力
- 成長動力
  - 傳染病病率增加
  - 製藥和生物技術公司數量不斷增加
  - 加強抗生素開發合作
  - 越來越關注學名藥
- 產業陷阱與挑戰
  - 抗生素抗藥性
  - 監理複雜性
成長潛力分析
管道評估
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀錶板

第 5 章：市場估計與預測：按藥物類別，2018-2032 年

主要趨勢
青黴素類
頭孢菌素類
大環內酯類
奎諾酮類
氨基糖苷類
四環素類
其他藥物類別

第 6 章：市場估計與預測：按類型，2018 - 2032

主要趨勢
品牌化
泛型

第 7 章：市場估計與預測：按頻譜分類，2018 - 2032 年

主要趨勢
廣效抗生素
窄譜抗生素

第 8 章：市場估計與預測：按藥物來源分類，2018 年 - 2032 年

主要趨勢
自然的
半合成
合成的

第 9 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

主要趨勢
口服
注射用
其他給藥途徑

第 10 章：市場估計與預測：按應用，2018 - 2032

主要趨勢
呼吸道感染
泌尿道感染（UTI）
皮膚和軟組織感染
性傳染感染（STI）
胃腸道感染
其他應用

第 11 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 12 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 13 章：公司簡介

Abbott Laboratories
AbbVie, Inc.
Allergan plc
Basilea Pharmaceutica Ltd.
Bayer AG
Bristol Myers Squibb
Cipla Inc.
Daiichi Sankyo Company Ltd.
Eli Lilly & Co.
GlaxoSmithKline plc.
Johnson & Johnson
Lupin Inc.
Melinta Therapeutics LLC
Merck & Co.
Novartis AG
Pfizer Inc.
Sandoz
Sanofi
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

簡介目錄

Product Code: 8014

The global antibiotics market is anticipated to record 3.3% CAGR from 2024 to 2032, owing to the escalating prevalence of infectious diseases worldwide.

As populations expand and urbanization accelerates, the risk of infectious outbreaks rises, necessitating heightened demand for effective antimicrobial treatments. According to the UN, the global population reached 8 billion in mid-November 2022 and will increase by nearly 2 billion people in the upcoming 30 years.

Additionally, the persistent challenge of antimicrobial resistance underscores the urgent need for innovative antibiotics. The increasing focus on healthcare infrastructure development, particularly in emerging economies, coupled with rising medical expenditure globally, amplifies the demand for antibiotics, driving the market forward.

The antibiotics market is classified based on drug class, type, spectrum, drug origin, route of administration, application, distribution channel, and region.

The penicillins segment is predicted to record strong demand by 2032, as they are known for their effectiveness against a wide range of bacterial infections, ranging from respiratory tract infections to skin infections. With the advancements in medical procedures and surgeries, the risk of postoperative infections has surged, necessitating antibiotics like penicillins for prophylactic and therapeutic purposes. The continuous development of novel formulations and the introduction of combination therapies bolster the demand for this drug class.

The generics type segment is expected to generate massive revenues by 2032, fueled by factors such as cost-effectiveness, ease of accessibility, and the expiration of patents for several branded antibiotics. Generic antibiotics offer a more affordable alternative to their branded counterparts, making them particularly attractive in both developed and developing markets. Additionally, stringent regulatory approvals and quality standards ensure the safety and efficacy of generic antibiotics, further driving their adoption globally.

Europe antibiotics market size will expand significantly through 2032 driven by factors such as a high prevalence of infectious diseases, well-established healthcare infrastructure, and strong government initiatives aimed at combating antimicrobial resistance. Countries across the region prioritize healthcare, leading to increased investments in R&D activities focused on novel antibiotic formulations and therapies. Furthermore, strategic collaborations between pharmaceutical companies and research institutions contribute to the region's prominence in the global antibiotics market.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data collection
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of infectious disease
  - 3.2.1.2 Rising number of pharmaceutical and biotechnology companies
  - 3.2.1.3 Growing collaborations for antibiotics development
  - 3.2.1.4 Increasing focus on generic medications
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Antibiotic resistance
  - 3.2.2.2 Regulatory complexities
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Regulatory landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

5.1 Key trends
5.2 Penicillins
5.3 Cephalosporins
5.4 Macrolides
5.5 Quinolones
5.6 Aminoglycosides
5.7 Tetracyclines
5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Branded
6.3 Generics

Chapter 7 Market Estimates and Forecast, By Spectrum, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Broad-spectrum antibiotics
7.3 Narrow-spectrum antibiotics

Chapter 8 Market Estimates and Forecast, By Drug Origin, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Natural
8.3 Semisynthetic
8.4 Synthetic

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 Oral
9.3 Parenteral
9.4 Other routes of administration

Chapter 10 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Million)

10.1 Key trends
10.2 Respiratory infections
10.3 Urinary tract infections (UTIs)
10.4 Skin and soft tissue infections
10.5 Sexually transmitted infections (STIs)
10.6 Gastrointestinal infections
10.7 Other applications

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

11.1 Key trends
11.2 Hospital pharmacies
11.3 Retail pharmacies
11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

12.1 Key trends, by region
12.2 North America
- 12.2.1 U.S.
- 12.2.2 Canada
12.3 Europe
- 12.3.1 Germany
- 12.3.2 UK
- 12.3.3 France
- 12.3.4 Spain
- 12.3.5 Italy
- 12.3.6 Rest of Europe
12.4 Asia Pacific
- 12.4.1 Japan
- 12.4.2 China
- 12.4.3 India
- 12.4.4 Australia
- 12.4.5 South Korea
- 12.4.6 Rest of Asia Pacific
12.5 Latin America
- 12.5.1 Brazil
- 12.5.2 Mexico
- 12.5.3 Rest of Latin America
12.6 Middle East & Africa
- 12.6.1 South Africa
- 12.6.2 Saudi Arabia
- 12.6.3 Rest of Middle East & Africa